Roche Holding AG logo

RO - Roche Holding AG Share Price

CHF322.8 6.8  2.2%

Last Trade - 17/01/20

Large Cap
Market Cap £219.46bn
Enterprise Value £228.48bn
Revenue £47.02bn
Position in Universe 3rd / 1047
Unlock RO Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


RO Revenue Unlock RO Revenue

Net Income

RO Net Income Unlock RO Revenue

Normalised EPS

RO Normalised EPS Unlock RO Revenue

PE Ratio Range

RO PE Ratio Range Unlock RO Revenue

Dividend Yield Range

RO Dividend Yield Range Unlock RO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RO EPS Forecasts Unlock RO Revenue
Profile Summary

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated April 13, 1966
Public Since May 4, 2001
No. of Shareholders: n/a
No. of Employees: 94,442
Sector Healthcare
Industry Pharmaceuticals
Index FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 300 Life Insurance , FTSEurofirst 300 , FTSEurofirst 300 Ex UK,
Exchange SIX Swiss Exchange
Shares in Issue 856,061,261
Free Float (0.0%)
Eligible for
RO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RO
Upcoming Events for RO
Thursday 30th January, 2020
Full Year 2019 Roche Holding AG Earnings Release
Thursday 30th January, 2020
Full Year 2019 Roche Holding AG Earnings Call
Thursday 6th February, 2020
Roche Holding AG to Discuss Data Presented at SMA Europe 2020 Call
Tuesday 3rd March, 2020
Roche Holding AG at Cowen HealthCare Conference
Wednesday 4th March, 2020
Roche Holding AG at Credit Suisse Global Healthcare Conference
Wednesday 4th March, 2020
Roche Holding AG at Daiwa Investment Conference - Tokyo
Tuesday 17th March, 2020
Roche Holding AG Annual Shareholders Meeting
Wednesday 25th March, 2020
Roche Holding AG at JPMorgan Global ESG Conference
Friday 27th March, 2020
Roche Holding AG at Kepler Cheuvreux Swiss Seminar
Wednesday 22nd April, 2020
Q1 2020 Roche Holding AG Corporate Sales Release
Wednesday 22nd April, 2020
Q1 2020 Roche Holding AG Corporate Sales Call
Similar to RO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.